Sucampo Pharmaceuticals, Inc. Class A

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson
PFEPfizer Inc.
ABBVAbbVie, Inc.
MRKMerck & Co., Inc.
BMYBristol-Myers Squibb Company
LLYEli Lilly and Company
NVSNovartis AG Sponsored ADR
AZNAstraZeneca PLC Sponsored ADR
GSKGlaxoSmithKline plc Sponsored ADR
NVONovo Nordisk A/S Sponsored ADR Class B
SNYSanofi Sponsored ADR
LCILannett Company, Inc.
AKTXAkari Therapeutics Plc Sponsored ADR

Company Profile

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. It operates through the following geographic segments: Asia, the Americas, and Europe. It offers Lubiprostone, which treats chronic constipation, chronic idiopathic constipation in adults, irritable bowel syndrome with constipation in adult women, and opiod-induced constipation in adults with chronic non-cancer pain. The company was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Rockville, MD.